Initiate VIDAZA® at appropriate diagnosis for improved survival1

Treatment with VIDAZA® initiated at diagnosis significantly increases overall survival in patients with intermediate-2 and high-risk MDSa compared with CCR.1 Learn how early treatment with VIDAZA® reduces transfusion burden, delays AML progression and leads to marked improvement in overall survival.

Learn more
Active older patients deserve active treatment

VIDAZA® is the first and only agent proven to improve overall survival vs. CCR in higher-risk MDSa patients aged 75 and older.1,2 Learn why its efficacy and tolerability make it a treatment of choice for these patients.3

Learn more
VIDAZA® has a well-characterized and manageable side effect profile

Awareness of adverse events (AEs) is important for correct treatment, permitting patients to continue therapy for maximum benefit.2 Learn more about proactive management of AEs to keep them on treatment.

Learn more
  1. #
  2. #
  3. #

VIDAZA® Treatment for MDSa

VIDAZA® is the first drug treatment to significantly prolong overall survival in higher-risk MDS patients and alter the natural history of the disease.1

  1. Fenaux P et al. Lancet Oncology 2009. 10:223-232.
  2. VIDAZA® Summary of Product Characteristics, 2011.
  3. Seymour JF et al. Crit Rev Oncol Hematol 2010 76: 218-227.
a. MDS-specific Indication

VIDAZA® is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with:

  • intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
  • chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder
b. AML-specific Indication:

Treatment of adult AML patients who are not eligible for haematopoietic stem cell transplantation with 20-30% blasts and multi-lineage dysplasia, according to the WHO classification. WHO classifies RAEB-T patients with blasts ?20% to <30% as AML patients.


This is an international website for VIDAZA® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

The information on this website is based on the European Summary of Product Characteristics (SmPC). Please refer to your country-specific website, or contact a Celgene representative in your country for the latest information specific to your country.